$NVAX upturn $6.97 Nasdaq GM A triple corrected
Post# of 22755
Posted On: 06/28/2016 6:59:16 PM
$NVAX upturn $6.97
Nasdaq GM
A triple corrected
called 12/6/13 $4.23
Website
Shares Outstanding: 270.78M
Float: 266.82M
% Held by Insiders: 3.36%
% Held by Institutions: 69.50%
Shares Short (as of May 31, 2016): 64.01M
Short Ratio (as of May 31, 2016): 12.11
Short % of Float (as of May 31, 2016): 28.28%
Shares Short (prior month): 64.89M
Headlines
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Nasdaq GM
A triple corrected
called 12/6/13 $4.23
Website
Shares Outstanding: 270.78M
Float: 266.82M
% Held by Insiders: 3.36%
% Held by Institutions: 69.50%
Shares Short (as of May 31, 2016): 64.01M
Short Ratio (as of May 31, 2016): 12.11
Short % of Float (as of May 31, 2016): 28.28%
Shares Short (prior month): 64.89M
Headlines
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
(0)
(0)Scroll down for more posts ▼